The global sepsis diagnostics market is expected to reach a value of USD 874.6 million by 2025. Rising prevalence of sepsis is the most significant factor anticipated to drive the market growth during the forecast period.
According to the National Center for Biotechnology Information, the number of patients suffering from septic poisoning rose by an average of 5.7% each year. As a result of this, there is a rising need for early diagnosis of such blood-poisoning diseases amongst patients. High prevalence of sepsis is also leading to a huge mortality rate, which is triggering early diagnosis to execute the clinical intervention.
Rising number of hospital-acquired infections are also expected to support the growth of the market over the forecast period. Hospital-acquired infections majorly include urinary tract & surgical site infections, which result into sepsis. According to WHO, 7 out of every 100 hospitalized patients develop hospital-acquired infections in developed countries. Thus, such infections significantly cause septicemia, which will raise the need for early diagnosis. On the other hand, pneumonia is also an important driving factor for high demand of sepsis diagnostics as it is one of the major causes for septic shock.
- Biomérieux SA
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- Roche Diagnostics
- Cepheid Inc.
- Beckman Coulter, Inc.
- Nanosphere, Inc.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Sepsis Diagnostics Market Variables, Trends & Scope
4 Sepsis Diagnostics Market: Product Estimates & Trend Analysis
5 Sepsis Diagnostics Market: Technology Estimates & Trend Analysis
6 Sepsis Diagnostics Market: Pathogen Estimates & Trend Analysis
7 Sepsis Diagnostics Market: Testing Type Estimates & Trend Analysis
8 Sepsis Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Technology, Pathogen, Testing Type
9 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/2p8cvb/sepsis